StreetInsider.com News Articles

Cantor Fitzgerald Starts Eikon Therapeutics Inc. (EIKN) at Overweight

Mon, 02 Mar 2026 06:12:43 +0000

Cantor Fitzgerald analyst Imogen Mansfield initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Overweight rating.

For an analyst ratings summary and ratings history on Eikon Therapeutics Inc. click here. For more ratings news on Eikon Therapeutics Inc. click here.

Shares of Eikon Therapeutics Inc. closed at $13.78 yesterday.

BofA Securities Starts Eikon Therapeutics Inc. (EIKN) at Buy

Mon, 02 Mar 2026 05:47:41 +0000

BofA Securities analyst Jason Zemansky initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Buy rating and a price target of $34.00.

The analyst comments "We initiate on Eikon with a Buy recommendation and a $34 PO. We believe drug developer Eikon’s discovery platform—a proprietary, high-resolution microscope capable of visualizing proteins in living cells—offers an unrivaled ability to generate novel, differentiated drug candidates. Some investors may be reluctant to assign much credit to platforms in biopharma, with some we spoke to admitting uncertainty over what the technology can deliver. Still, we think the market may be overlooking its potential to

BofA Securities Starts Eikon Therapeutics Inc. (EIKN) at Buy

Mon, 02 Mar 2026 05:47:41 +0000

BofA Securities analyst Jason Zemansky initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Buy rating and a price target of $34.00.

Mizuho Starts Eikon Therapeutics Inc. (EIKN) at Outperform

Mon, 02 Mar 2026 04:53:17 +0000

Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Outperform rating and a price target of $26.00.

The analyst comments "We are initiating coverage of Eikon with an Outperform rating and $26 PT. Eikon's single-molecule tracking (SMT) platform represents a novel and differentiated approach to drug discovery that has the opportunity to accelerate discovery timelines and potentially increase probabilities of clinical success. We expect the SMT platform to be a robust source of potential best-in-class and/or first-in-class programs across multiple therapeutic areas. EIK1005 is a WRN inhibitor with best-in-class potential now entering Phase I development. It

Mizuho Starts Eikon Therapeutics Inc. (EIKN) at Outperform

Mon, 02 Mar 2026 04:53:17 +0000

Mizuho analyst Joseph Catanzaro initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Outperform rating and a price target of $26.00.

Morgan Stanley Starts Eikon Therapeutics Inc. (EIKN) at Overweight

Mon, 02 Mar 2026 02:14:48 +0000

Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Overweight rating and a price target of $32.00.

The analyst comments: "Our Overweight thesis is anchored on four core elements: 1. EIK1001 is competitive in 1L non-small cell lung cancer. Phase 2 data for EIK1001 + Keytruda (pembrolizumab) and chemotherapy show a 60% ORR (71% in squamous and 56% in non-squamous) with a well-tolerated safety profile, comparing favorably with historical PD-1 + chemo benchmarks set by Keytruda. EIK1001 is also progressing in registrational studies for melanoma. 2. PARP1-selective EIK1003/1004 offer meaningful upside. EIK1003 has shown monotherapy

Morgan Stanley Starts Eikon Therapeutics Inc. (EIKN) at Overweight

Mon, 02 Mar 2026 02:14:48 +0000

Morgan Stanley analyst Sean Laaman initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Overweight rating and a price target of $32.00.

JPMorgan Starts Eikon Therapeutics Inc. (EIKN) at Overweight

Mon, 02 Mar 2026 02:08:31 +0000

JPMorgan analyst Brian Cheng initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Overweight rating and a price target of $29.00.

The analyst comments: "We initiate coverage on EIKN with an OW rating and a Dec2026 price target of $29. EIKN’s portfolio, led by Keytruda ex-developers, is strategically positioned with two advanced assets through in-licenses and a homegrown pipeline built from its super resolution microscopy discovery engine. We believe the TLR7/8 agonist (EIK1001) has the attractive ability to move the needle beyond what the gold standard IO regimen can offer today in lung cancer and melanoma, underpinned by the combo’s

JPMorgan Starts Eikon Therapeutics Inc. (EIKN) at Overweight

Mon, 02 Mar 2026 02:08:31 +0000

JPMorgan analyst Brian Cheng initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Overweight rating and a price target of $29.00.

Wedbush Starts Eikon Therapeutics Inc. (EIKN) at Underperform

Thu, 26 Feb 2026 07:05:36 +0000

(Updated - February 26, 2026 7:05 AM EST)

Wedbush analyst Robert Driscoll initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Underperform rating and a price target of $7.00.

The analyst comments "EIKN is developing a pipeline of therapies for the treatment of cancer, including in-licensed assets and internal candidates developed using its technology platform. Lead program EIK1001 is a systemically-administered TLR7/8 agonist, a class of agents that have failed to gain significant traction

Wedbush Starts Eikon Therapeutics Inc. (EIKN) at Underperform

Thu, 26 Feb 2026 07:05:36 +0000

(Updated - February 26, 2026 7:05 AM EST)

Wedbush analyst Robert Driscoll initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Underperform rating and a price target of $7.00.

Wedbush Starts Eikon Therapeutics Inc. (EIKN) at Underperform

Thu, 26 Feb 2026 07:05:36 +0000

(Updated - February 26, 2026 7:05 AM EST)

Wedbush analyst Robert Driscoll initiates coverage on Eikon Therapeutics Inc. (NASDAQ: EIKN) with a Underperform rating and a price target of $7.00.

Eikon Therapeutics Opens At $17.05, IPO Priced At $18

Thu, 05 Feb 2026 12:43:56 +0000

Eikon Therapeutics Opens At $17.05, IPO Priced At $18

Eikon Therapeutics prices upsized IPO at $18 per share

Wed, 04 Feb 2026 19:59:16 +0000

Eikon Therapeutics, Inc. (NASDAQ: EIKN) announced the pricing of its upsized initial public offering of 21,177,600 shares of common stock at $18.00 per share. The biopharmaceutical company granted underwriters a 30-day option to purchase up to an additional 3,176,640 shares at the same price.

The company expects gross proceeds of approximately $381 million from the offering, before deducting underwriting discounts, commissions and offering expenses. The figures do not include potential proceeds from the underwriters' option to purchase additional shares.